Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTI-015 in Recurrent Glioblastoma Multiforme
NCT00006656Phase 2Unknown
- Start
- Jun 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carmustine in glioblastoma multiforme (GBM). Primary endpoints: Maximum Tolerated Dose, Qualitative and Quantitative Toxicity and 2 more. Status: unknown.
02
Drugs
carmustine
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00006656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006656.